Examining Endothelial Dysfunction and The Effect of Topical
Treatment with Prostaglandin E1 In Diabetics Suffering from
Erectile Dysfunction

J 2020

Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction

ŠRÁMKOVÁ, Taťána, K. ŠRÁMKOVÁ, Jiří JARKOVSKÝ, Michal POHANKA, Aleš ČERMÁK et. al.

Základní údaje

Originální název

Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction

Autoři

ŠRÁMKOVÁ, Taťána (203 Česká republika, garant, domácí), K. ŠRÁMKOVÁ (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Michal POHANKA (203 Česká republika, domácí) a Aleš ČERMÁK (203 Česká republika, domácí)

Vydání

Biomedical Journal of Scientific & Technical Research, Westchester, Biomedical Research Network, 2020, 2574-1241

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30217 Urology and nephrology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/20:00117461

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.26717/BJSTR.2020.26.004386

Klíčová slova anglicky

Erectile Dysfunction; Diabetes Type 2; Endothelial Dysfunction; Topical Alprostadil; International Index of Erectile Function; Erectile Hardness Score

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 12. 2020 06:54, Mgr. Tereza Miškechová

Anotace

V originále

Aims: Erectile and endothelial dysfunctions are the most common complications of diabetes. We studied the endothelial function and response to treatment of a topical alprostadil in diabetics with erectile dysfunction. Sample and Methods: 30 patients were enrolled in the non-intervention, postregistration, prospective study with 300 (MU)g alprostadil cream. We examined vascular endothelial function using an ENDO-PAT 2000 device. We used International Index of Erectile Function (IIEF-5), Erectile Hardness Score (EHS), Global Assessment Questionnaire (GAQ) and Sexual Encounter Profile Q 2 and 3 (SEP 2, SEP 3) to assess erectile function. The primary outcome measures were the proportion of patients with an optimal treatment response at baseline and at 6 and 12 weeks after treatment and the evaluation of patients and their partner’s subjective satisfaction. Results: We diagnosed endothelial dysfunction in 15 diabetics. After 12 weeks of treatment with alprostadil 53.3% of the sample, reached normal erectile function. We found a significant increase in IIEF-5 scores with a median of 6 points (range 0–19, p<0.001) after 6 weeks compared to baseline, and of 7 points (range 0–20, p<0.001) after 12 weeks of treatment compared to baseline; a significant increase occurred both after 6 and 12 weeks of treatment (p=0.002). After both 6 and 12 weeks we found a significant increase in erection rigidity, EHS, compared to baseline (p< 0.001, p = 0.014). After 12 weeks of treatment, GAQ, improving erectile function was reached in 76.7% patients. Conclusion: We have demonstrated that topical alprostadil is efficient in diabetic men with erectile-endothelial dysfunction.

Citovat

ŠRÁMKOVÁ, Taťána, K. ŠRÁMKOVÁ, Jiří JARKOVSKÝ, Michal POHANKA a Aleš ČERMÁK. Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction. Biomedical Journal of Scientific & Technical Research. Westchester: Biomedical Research Network, 2020, roč. 26, č. 4, s. 20160-20166. ISSN 2574-1241. Dostupné z: https://dx.doi.org/10.26717/BJSTR.2020.26.004386.

@article{1713418,
   author = {Šrámková, Taťána and Šrámková, K. and Jarkovský, Jiří and Pohanka, Michal and Čermák, Aleš},
   article_location = {Westchester},
   article_number = {4},
   doi = {http://dx.doi.org/10.26717/BJSTR.2020.26.004386},
   keywords = {Erectile Dysfunction; Diabetes Type 2; Endothelial Dysfunction; Topical Alprostadil; International Index of Erectile Function; Erectile Hardness Score},
   language = {eng},
   issn = {2574-1241},
   journal = {Biomedical Journal of Scientific & Technical Research},
   title = {Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction},
   url = {https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php},
   volume = {26},
   year = {2020}
}

TY  - JOUR
ID  - 1713418
AU  - Šrámková, Taťána - Šrámková, K. - Jarkovský, Jiří - Pohanka, Michal - Čermák, Aleš
PY  - 2020
TI  - Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction
JF  - Biomedical Journal of Scientific & Technical Research
VL  - 26
IS  - 4
SP  - 20160-20166
EP  - 20160-20166
PB  - Biomedical Research Network
SN  - 25741241
KW  - Erectile Dysfunction
KW  - Diabetes Type 2
KW  - Endothelial Dysfunction
KW  - Topical Alprostadil
KW  - International Index of Erectile Function
KW  - Erectile Hardness Score
UR  - https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php
L2  - https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php
N2  - Aims: Erectile and endothelial dysfunctions are the most common complications of diabetes. We studied the endothelial function and response to treatment of a topical alprostadil in diabetics with erectile dysfunction. Sample and Methods: 30 patients were enrolled in the non-intervention, postregistration, prospective study with 300 (MU)g alprostadil cream. We examined vascular endothelial function using an ENDO-PAT 2000 device. We used International Index of Erectile Function (IIEF-5), Erectile Hardness Score (EHS), Global Assessment Questionnaire (GAQ) and Sexual Encounter Profile Q 2 and 3 (SEP 2, SEP 3) to assess erectile function. The primary outcome measures were the proportion of patients with an optimal treatment response at baseline and at 6 and 12 weeks after treatment and the evaluation of patients and their partner’s subjective satisfaction. Results: We diagnosed endothelial dysfunction in 15 diabetics. After 12 weeks of treatment with alprostadil 53.3% of the sample, reached normal erectile function. We found a significant increase in IIEF-5 scores with a median of 6 points (range 0–19, p<0.001) after 6 weeks compared to baseline, and of 7 points (range 0–20, p<0.001) after 12 weeks of treatment compared to baseline; a significant increase occurred both after 6 and 12 weeks of treatment (p=0.002). After both 6 and 12 weeks we found a significant increase in erection rigidity, EHS, compared to baseline (p< 0.001, p = 0.014). After 12 weeks of treatment, GAQ, improving erectile function was reached in 76.7% patients. Conclusion: We have demonstrated that topical alprostadil is efficient in diabetic men with erectile-endothelial dysfunction.
ER  -

ŠRÁMKOVÁ, Taťána, K. ŠRÁMKOVÁ, Jiří JARKOVSKÝ, Michal POHANKA a Aleš ČERMÁK. Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction. \textit{Biomedical Journal of Scientific \&{} Technical Research}. Westchester: Biomedical Research Network, 2020, roč.~26, č.~4, s.~20160-20166. ISSN~2574-1241. Dostupné z: https://dx.doi.org/10.26717/BJSTR.2020.26.004386.

Podrobný výpis o publikaci